Corium Receives US Patent for Dissolving “Drug-in-Tip” MicroCor Transdermal Patches
Corium recently announced the issuance of a patent relating the company’s unique dissolving “Drug-in-Tip” MicroCor transdermal patch, which enables the needle-free delivery of biologics, vaccines, and small molecules through the skin.
To date, the MicroCor technology has been evaluated in extensive preclinical studies and just completed a Phase IIa study, accessing the delivery of parathyroid hormone, which is used in the treatment of osteoporosis. Those data were quite positive, demonstrating rapid drug uptake, significant increases in bone formation biomarkers, and excellent skin tolerability.
The MicroCor dissolving drug-in-tip platform offers patients a needle-free alternative to injections with short wear time, a flexible range of drug-release profiles, and enhanced safety due to the absence of sharps left behind after use. The life of the new patent extends at least until September 2031.
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture, and commercialization of specialty pharmaceutical products that leverage the company’s advanced transdermal and transmucosal delivery systems. Corium has developed and is the sole commercial manufacturer of six prescription drug and consumer products with partners Teva Pharmaceuticals, Par Pharmaceutical, and Procter & Gamble. The company has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis and neurologic disorders. For more information, visit www.coriumgroup.com.
Total Page Views: 536